NCT04907643 2026-02-20
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
Phase NA Recruiting
Clinical Trials
45 trialsNCT07377487 2026-02-20
INDIGO
Boston Scientific Corporation
Phase NA Recruiting
NCT04104529 2026-02-05
BCB RIV
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Recruiting
NCT06788886 2025-12-30
Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases
Mayo Clinic
Phase NA Recruiting
NCT06735560 2025-12-08
ELEGANCE
Nantes University Hospital
Phase NA Recruiting
NCT02743741 2025-12-03
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
University Health Network, Toronto
Phase NA Active not recruiting
NCT03217097 2025-11-21
MGMT-NET
Hospices Civils de Lyon
Phase NA Completed
NCT05017662 2025-09-04
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
Ariceum Therapeutics GmbH
Phase NA Completed
NCT06908629 2025-08-26
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
Barbara Ann Karmanos Cancer Institute
Phase NA Recruiting
NCT07014254 2025-06-10
Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
Xijing Hospital
Phase NA Not yet recruiting
NCT06204159 2025-05-20
Trinav
Abramson Cancer Center at Penn Medicine
Phase NA Active not recruiting
NCT06263088 2025-05-07
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Case Comprehensive Cancer Center
Phase NA Recruiting
NCT05443087 2025-03-30
TARGETMONITO
UNICANCER
Phase NA Recruiting
NCT06881511 2025-03-30
Exploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase NA Recruiting
NCT04804371 2025-03-28
Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
University Health Network, Toronto
Phase NA Active not recruiting
NCT05680675 2025-02-06
Dual-Tracer Theranostic PET
University of Utah
Phase NA Completed
NCT05255133 2025-01-06
Liquid-NET
Universiteit Antwerpen
Phase NA Completed
NCT04584008 2024-10-15
VISIONARY
Peking University
Phase NA Active not recruiting
NCT06121752 2024-10-15
DNET
Asian Institute of Gastroenterology, India
Phase NA Unknown
NCT03288402 2024-06-20
DIB-NET
University Hospitals Coventry and Warwickshire NHS Trust
Phase NA Completed
NCT02472678 2024-05-06
WIN
University Medical Center Groningen
Phase NA Completed
NCT02481804 2024-05-06
DIVIT-pilot
University Medical Center Groningen
Phase NA Completed
NCT03143946 2024-05-06
DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor
University Medical Center Groningen
Phase NA Completed
NCT06321692 2024-03-20
Early Identification of Cardiac Involvement in Patients With Carcinoid: Clinical and Prognostic Implications
European Institute of Oncology
Phase NA Recruiting
NCT03834701 2024-02-13
RAPNEN
Catholic University of the Sacred Heart
Phase NA Completed
NCT03873870 2024-01-17
68Ga-DOTATATE PET for Management of Neuroendocrine Tumors
University Health Network, Toronto
Phase NA Completed
NCT03986593 2023-07-05
Cryoablation of Bone Metastases From Endocrine Tumors
Instituto do Cancer do Estado de São Paulo
Phase NA Terminated
NCT05513469 2023-04-07
Radio-Marker
Erasmus Medical Center
Phase NA Unknown
NCT04077372 2023-01-27
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
Stanford University
Phase NA Terminated
NCT05268952 2022-03-07
A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)
University Hospital, Antwerp
Phase NA Unknown
NCT02609737 2022-02-01
Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT04073017 2021-05-21
Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency
Vanderbilt-Ingram Cancer Center
Phase NA Terminated
NCT04790708 2021-03-10
FENET-2016
University Hospital of Ferrara
Phase NA Unknown
NCT01476592 2019-11-18
A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors
University of Wisconsin, Madison
Phase NA Completed
NCT02125474 2019-11-14
Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate
Instituto Nacional de Cancerologia, Columbia
Phase NA Completed
NCT04152928 2019-11-06
Applying PET/MR in Neuroendocrine Tumors - Imaging Dynamic Processes in Both Modalities
Tel-Aviv Sourasky Medical Center
Phase NA Unknown
NCT04154241 2019-11-06
Developing a Method Using PET-MR to Improve Staging and Monitoring of Neuroendocrine Tumor
Tel-Aviv Sourasky Medical Center
Phase NA Unknown
NCT02882503 2019-07-24
Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Small Benign Pancreatic Tumors
National Taiwan University Hospital
Phase NA Withdrawn
NCT03622333 2018-08-20
Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines)
CHU de Reims
Phase NA Unknown
NCT03183271 2017-06-14
Proton Boost for Locally Advanced HEAD AND NECK TUMORS
CNAO National Center of Oncological Hadrontherapy
Phase NA Completed
NCT01902238 2016-12-01
EUS
Asan Medical Center
Phase NA Unknown
NCT01099228 2016-07-21
Combination Targeted Radiotherapy in Neuroendocrine Tumors
University of Iowa
Phase NA Completed
NCT02539433 2015-09-03
Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)
Northwell Health
Phase NA Completed
NCT02246322 2014-09-22
EUS-FNA
Istituto Clinico Humanitas
Phase NA Unknown
NCT00230139 2008-10-15
SPECT/CT in Endocrine and Neuroendocrine Tumors
Rambam Health Care Campus
Phase NA Completed